Christina S. Dalboge-Eickhardt

Roskilde, 4000, Denmark

Last Updated: 09/26/2026

Save publications for later

Sign Up

Not sure about your diagnosis?

Check Your Symptoms

Found 12 publications

Mathematical modeling of JAK2V617F clonal expansion in a general population cohort.

Mathematical modeling of JAK2V617F clonal expansion in a general population cohort.

Journal: Proceedings of the National Academy of Sciences of the United States of America

Published: June 17, 2026

Hierarchical mathematical modelling of patients with myeloproliferative neoplasms captures interferon-α treatment responses and allows for personalised and population predictions.

Hierarchical mathematical modelling of patients with myeloproliferative neoplasms captures interferon-α treatment responses and allows for personalised and population predictions.

Journal: Mathematical biosciences

Published: January 22, 2026

The JAK2V617F and CALR mutations and risk of cancer, cardiovascular diseases, and all-cause mortality.

The JAK2V617F and CALR mutations and risk of cancer, cardiovascular diseases, and all-cause mortality.

Journal: Journal of internal medicine

Published: November 06, 2025

Statins enhance the efficacy of pegylated interferon-alfa2 in Philadelphia-negative chronic myeloproliferative neoplasms.

Statins enhance the efficacy of pegylated interferon-alfa2 in Philadelphia-negative chronic myeloproliferative neoplasms.

Journal: Blood advances

Published: April 29, 2025

Anaplasmosis imitating haematological disease with hyperinflammation

Anaplasmosis imitating haematological disease with hyperinflammation

Journal: Ugeskrift for laeger

Published: March 24, 2025

Combination therapy with ruxolitinib and pegylated interferon alfa-2a in newly diagnosed patients with polycythemia vera.

Combination therapy with ruxolitinib and pegylated interferon alfa-2a in newly diagnosed patients with polycythemia vera.

Journal: Blood advances

Published: March 14, 2024

Mathematical modelling of stem and progenitor cell dynamics during ruxolitinib treatment of patients with myeloproliferative neoplasms.

Mathematical modelling of stem and progenitor cell dynamics during ruxolitinib treatment of patients with myeloproliferative neoplasms.

Journal: Frontiers in immunology

Published: February 09, 2024

JAK2V617F drives gut microbiota differences in patients with myeloproliferative neoplasms.

JAK2V617F drives gut microbiota differences in patients with myeloproliferative neoplasms.

Journal: European journal of haematology

Published: November 16, 2023

Neutrophil-to-lymphocyte ratio and all-cause mortality with and without myeloproliferative neoplasms-a Danish longitudinal study.

Neutrophil-to-lymphocyte ratio and all-cause mortality with and without myeloproliferative neoplasms-a Danish longitudinal study.

Journal: Blood cancer journal

Published: September 28, 2023

Pronounced gut microbiota signatures in patients with JAK2V617F-positive essential thrombocythemia.

Pronounced gut microbiota signatures in patients with JAK2V617F-positive essential thrombocythemia.

Journal: Microbiology spectrum

Published: September 11, 2023

The gut microbiota in patients with polycythemia vera is distinct from that of healthy controls and varies by treatment.

The gut microbiota in patients with polycythemia vera is distinct from that of healthy controls and varies by treatment.

Journal: Blood advances

Published: July 13, 2022

Clonal haematopoiesis of indeterminate potential and impaired kidney function-A Danish general population study with 11 years follow-up.

Clonal haematopoiesis of indeterminate potential and impaired kidney function-A Danish general population study with 11 years follow-up.

Journal: European journal of haematology

Published: May 26, 2022

Showing 1-12 of 12

Last Updated: 09/26/2026